Transmural Systems

Transmural Systems is a private U.S. medical device company developing and commercializing transcatheter electrosurgical therapies for structural heart and cardiovascular disease. The company focuses on minimally invasive devices intended to simplify complex cardiac interventions, particularly in valve disease, hypertrophic cardiomyopathy, and heart failure. Its lead product, the TELLTALE Electrosurgical Guidewire System, received FDA 510(k) clearance in November 2025 for preventing coronary obstruction during transcatheter aortic valve replacement procedures. Beyond TELLTALE, the company describes a broader platform that includes Sesame for transcatheter myotomy and Mirth for intramural remodeling ventriculoplasty. Transmural Systems appears to be a clinically advanced, privately held structural heart device developer funded largely through non-dilutive federal support.